Chemed (CHE) Competitors

Medpace (NASDAQ:MEDP) and Chemed (NYSE:CHE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Which has more risk and volatility, MEDP or CHE?

Medpace has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of MEDP or CHE?

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 20.3% of Medpace shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is MEDP or CHE more profitable?

Medpace has a net margin of 18.74% compared to Chemed's net margin of 11.56%. Medpace's return on equity of 67.66% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	18.74%	67.66%	21.86%
Chemed	11.56%	25.83%	17.77%

Which has preferable earnings and valuation, MEDP or CHE?

Medpace has higher earnings, but lower revenue than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.11B	5.73	$404.39M	$13.45	32.00
Chemed	$2.43B	2.57	$302M	$19.45	22.03

Does the media refer more to MEDP or CHE?

In the previous week, Chemed had 9 more articles in the media than Medpace. MarketBeat recorded 28 mentions for Chemed and 19 mentions for Medpace. Medpace's average media sentiment score of 1.24 beat Chemed's score of 0.39 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	14 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	10 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Do analysts prefer MEDP or CHE?

Medpace presently has a consensus target price of $406.60, suggesting a potential downside of 5.52%. Chemed has a consensus target price of $579.75, suggesting a potential upside of 35.31%. Given Chemed's stronger consensus rating and higher possible upside, analysts clearly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	3 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Chemed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Medpace beats Chemed on 9 of the 16 factors compared between the two stocks.